Pacira Pharmaceuticals, Inc. (PCRX): From Top to Bottom

Pacira Pharmaceuticals, Inc. (PCRX) is an interesting player in the Healthcare space, with a focus on Drugs – Generic. The stock has been active on the tape, currently trading at $36.35, down from yesterday’s close by -2.81%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.

Fundamental Analysis

Pacira Pharmaceuticals, Inc. (PCRX) currently trades with a market capitalization of $1.47 Billion. That value represents a market adjusting for revenues that have been falling by -1.49 % on a quarterly year/year basis as of the company’s last quarterly report.

You can get a sense of how sustainable that is by a levered free cash flow of -$870 Thousand over the past twelve months. Generally speaking, earnings are expected to fall in coming quarters. Analysts are forecasting earnings of $0.1 on a per share basis this quarter. Perhaps, that suggests something about why 0.88% of the outstanding share supply is held by institutional investors.

Technical Analysis

No analysis is ever complete without a thorough survey of a stock’s technical behavior. Looking at the stock’s movement on the chart, Pacira Pharmaceuticals, Inc. recorded a 52-week high of $58.95. It is now trading 22.6% off that level. The stock is trading $41.69 its 50-day moving average by 5.34%. The stock carved out a 52-week low down at $29.81.

In recent action, Pacira Pharmaceuticals, Inc. (PCRX) has made a move of -12.41% over the past month, which has come on weak relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 12.51, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 8.03% with $40.37 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of PCRX.

Previous articleTaking a Fresh Look at The Gap, Inc. (GPS)
Next articleDrilling Down Into Dollar General Corporation (DG)